CliffBio
small molecule

PROMACTA

ELTROMBOPAG OLAMINE

Loss of exclusivityFebruary 2028latest FDA-listed patent expiry
CompanyNovartis →View the full company profile on CliffBio

Drug detail

Brand namePROMACTA
Active ingredientELTROMBOPAG OLAMINE
StrengthEQ 12.5MG ACID
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2011
Marketing statusRX

Listed patents

PatentExpiresType
8052994*PEDFebruary 2028—
8828430*PEDFebruary 2028—
8071129*PEDFebruary 2028—
8062665*PEDFebruary 2028—
8052993*PEDFebruary 2028—
8071129August 2027product
8052994August 2027product
8828430August 2027product
8062665August 2027product
8052993August 2027product
7547719*PEDJanuary 2026—
7547719July 2025substance, product

More from Novartis

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

PROMACTA patent cliff — loss of exclusivity February 2028 | CliffBio